Invokana, containing the active ingredient canagliflozin, is a medication used to manage type 2 diabetes. It belongs to a class of drugs known as sodium-glucose cotransporter-2 (SGLT2) inhibitors [1].
How does Invokana work?
Invokana functions by inhibiting SGLT2 in the kidneys. This inhibition reduces the reabsorption of glucose, leading to increased glucose excretion in the urine and thereby lowering blood glucose levels [1].
What conditions does Invokana treat?
Invokana is prescribed to improve glycemic control in adults with type 2 diabetes mellitus. It is also indicated to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease [1]. Additionally, it is used to reduce the risk of end-stage kidney disease, doubling of serum creatinine, and cardiovascular death in patients with type 2 diabetes mellitus and diabetic nephropathy with albuminuria [1].
What is the typical dosage for Invokana?
The recommended starting dose for Invokana is 100 mg once daily. Doses can be increased to 300 mg once daily as needed to improve glycemic control [1].
What are the potential side effects of Invokana?
Common side effects associated with Invokana include urinary tract infections and genital mycotic infections [1]. Other reported side effects can include dehydration, dizziness, and changes in urination patterns. Serious risks include Fournier's gangrene, a rare but severe infection of the tissue under the skin [1].
How long does Invokana's patent protection last?
Patent information for pharmaceuticals can be complex and may vary by region. DrugPatentWatch.com tracks patent expirations for drugs like Invokana [2]. Generally, drug patents provide market exclusivity for a set period, but the exact expiry dates and potential for extensions or challenges influence when generic versions can enter the market [2].
Can generic versions of Invokana be available?
The availability of generic canagliflozin depends on the expiration of patents and any other market exclusivity rights. Once these protections expire, other pharmaceutical companies may seek approval to manufacture and market generic versions of Invokana, potentially leading to lower costs [2].
How does Invokana compare to other diabetes medications?
Invokana, as an SGLT2 inhibitor, offers a different mechanism of action compared to other classes of diabetes drugs such as metformin (a biguanide) or sulfonylureas. While all aim to lower blood glucose, SGLT2 inhibitors also have demonstrated cardiovascular and renal benefits, which are significant differentiating factors [1].
What clinical data supports Invokana's use?
Clinical trials have demonstrated Invokana's efficacy in reducing HbA1c levels, body weight, and systolic blood pressure. Furthermore, studies have shown its ability to decrease the risk of cardiovascular events and progression of diabetic kidney disease [1].
Who manufactures Invokana?
Invokana is manufactured by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson [1].
Are there any contraindications for Invokana?
Invokana is contraindicated in patients with known hypersensitivity to canagliflozin or any of its excipients. It is also not recommended for patients with a history of serious hypersensitivity reactions to canagliflozin [1].
*
**Sources:
[1] Drug label information for Invokana (canagliflozin).
[2] DrugPatentWatch.com.